PD 16 - Lung 4 - Poster Discussion
1138 - Impact of Intensity Modulated Radiation Therapy on Acute Toxicity in Locally Advanced Lung Cancer: Results of a Large Statewide Multi-center Cohort
Wednesday, October 24
11:18 AM - 11:24 AM
Location: Room 217 C/D
Shruti Jolly, MD
University of Michigan: Associate Professor: Employee, Faculty: Employee
Impact of Intensity Modulated Radiation Therapy on Acute Toxicity in Locally Advanced Lung Cancer: Results of a Large Statewide Multi-center Cohort
S. Jolly1, M. Schipper2, Y. Sun2, P. A. Paximadis3, L. L. Kestin4, I. S. Grills5, B. Movsas6, T. P. Boike7, M. Wilson4, M. M. Matuszak8, L. J. Pierce1, and J. A. Hayman1; 1Michigan Medicine, Ann Arbor, MI, 2Department of Biostatistics, University of Michigan, Ann Arbor, MI, 3Lakeland Radiation Oncology, St. Joseph, MI, 4Michigan Healthcare Professionals, 21st Century Oncology, Farmington Hills, MI, 5Beaumont Health, Royal Oak, MI, 6Henry Ford Health System, Detroit, MI, 7McLaren Northern Michigan, Petoskey, MI, 8Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
Purpose/Objective(s): Secondary analysis of RTOG 0617 has shown lower rates of pneumonitis and less decline in patient quality of life with the use of intensity modulated radiation therapy (IMRT) versus three-dimensional conformal external beam radiation therapy (3D-CRT) in locally advanced non-small cell lung cancer patients undergoing definitive radiation therapy. In a large statewide radiation oncology quality consortium, we sought to evaluate impact of IMRT vs. 3D-CRT treatment technique on acute esophagitis and pneumonitis. Materials/Methods: From 2013 to 2017, 1919 patients with non-metastatic lung cancer were enrolled in the consortium. Physician reported toxicity by CTCAE and patient reported outcomes using FACT Lung Cancer Subscale (LCS) and FACT Trials Outcome Index (TOI) were collected at 1, 3 and 6 months from the end of radiation. We compared physician and patient reported quality of life by treatment technique. Normal tissue dose volume constraints and PTV objectives were not prospectively controlled. To account for differences in prognostic factors between IMRT and 3D-CRT patients, we performed inverse probability of treatment weighting (IPTW) via a propensity score. The propensity score was estimated via a logistic regression model and included age, smoking status, comorbidities, stage, PTV volume, chemotherapy, prescription dose, total number of structures and individual structures (e.g. esophagus, heart) within 2cm of the PTV. Results: 1237 non-surgical locally advanced lung cancer patients met inclusion criteria. After excluding patients with missing variables, 1062 (86%) were included in the analysis. 31% were treated with 3D-CRT and 69% were treated with IMRT. Compared with 3D-CRT patients, IMRT patients had significantly larger PTVs (mean 370 vs 474cc) and were more likely to be stage IIIB (24% vs 32%). In logistic regression models using IPTW, there were no significant differences between 3D-CRT and IMRT in rates of esophagitis (Odds Ratio =0.95; 95% CI=0.70, 1.32; p=0.76) or pneumonitis (OR = 0.91; 95% CI:0.43, 1.92; p=0.80). At 6 months after completion of RT with a compliance of 45%, 3D-CRT and IMRT resulted in similar proportions of patient experiencing a decline of at least 2 points on LCS (38% vs 45%, p=0.33) and at least 5 points on TOI (48% vs 54%, p=0.72). Conclusion: In these data from a statewide consortium of academic and community radiation oncology practices, despite the PTV being larger among patients treated with IMRT vs 3D-CRT, no significant difference in acute esophagitis or pneumonitis by radiation treatment technique was found. Further analysis is underway seeking to use patient variables and dose relationships to identify a subgroup of patients in which IMRT may reduce toxicity relative to 3D-CRT.
Author Disclosure: S. Jolly: None. M. Schipper: None. Y. Sun: None. P.A. Paximadis: None. L.L. Kestin: board member; Michigan Healthcare Professionals. National Director of Thoracic & Lung Care Services; 21st Century Oncology. I.S. Grills: Board of Directors; Greater Michigan Gamma Knife. B. Movsas: Research Grant; Varian Medical Systems, Inc, Philips, Inc, NCI. Travel Expenses; Varian Medical Systems, Inc, Philips, Inc. Patent/License Fees/Copyright; Henry Ford Health System. Chair, Quality of Life Subcommittee; Radiation Therapy Oncology Group/NRG. T.P. Boike: Partner; Petoskey Radiation Oncology. Honoraria; ASTRO APEx Reviewer. Member; NCI Prostate Cancer Task Force. M. Wilson: None. M.M. Matuszak: Employee; William Beaumont Hospital. L.J. Pierce: Royalty; UpToDate. J.A. Hayman: Research Grant; Blue Cross Blue Shield of Michigan.